NCT04963153View on ClinicalTrials.gov

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Urothelial CarcinomaRecurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaRecurrent Urethral Urothelial CarcinomaRecurrent Urothelial CarcinomaStage IIIB Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo echocardiography

DRUG

Enfortumab Vedotin

Given IV

DRUG

Erdafitinib

Given PO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

Trial Locations (10)

10065

NYP/Weill Cornell Medical Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

80045

UCHealth University of Colorado Hospital, Aurora

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH